Cargando…

Molecularly Self-Assembled Nucleic Acid Nanoparticles for Targeted In Vivo siRNA Delivery

Nanoparticles are employed for delivering therapeutics into cells(1,2). However, size, shape, surface chemistry and the presentation of targeting ligands on the surface of nanoparticles can affect circulation half-life and biodistribution, cell specific internalization, excretion, toxicity, and effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hyukjin, Lytton-Jean, Abigail K. R., Chen, Yi, Love, Kevin T., Park, Angela I., Karagiannis, Emmanouil D., Sehgal, Alfica, Querbes, William, Zurenko, Christopher S., Jayaraman, Muthusamy, Peng, Chang G., Charisse, Klaus, Borodovsky, Anna, Manoharan, Muthiah, Donahoe, Jessica S., Truelove, Jessica, Nahrendorf, Matthias, Langer, Robert, Anderson, Daniel G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898745/ https://www.ncbi.nlm.nih.gov/pubmed/22659608 http://dx.doi.org/10.1038/nnano.2012.73

Ejemplares similares

Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling
por: Sahay, Gaurav, et al.
Publicado: (2013)

Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
por: Foster, Donald J., et al.
Publicado: (2018)

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells
por: Novobrantseva, Tatiana I, et al.
Publicado: (2012)

Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification
por: Chan, Amy, et al.
Publicado: (2015)

Acyclic (S)-glycol nucleic acid (S-GNA) modification of siRNAs improves the safety of RNAi therapeutics while maintaining potency
por: Egli, Martin, et al.
Publicado: (2023)

Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression
por: Willoughby, Jennifer L.S., et al.
Publicado: (2018)

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
por: Nair, Jayaprakash K., et al.
Publicado: (2017)

Identification of siRNA delivery enhancers by a chemical library screen
por: Gilleron, Jerome, et al.
Publicado: (2015)

Modulation of thermal stability can enhance the potency of siRNA
por: Addepalli, Haripriya, et al.
Publicado: (2010)

Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles
por: Mui, Barbara L, et al.
Publicado: (2013)

Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
por: Jayaraman, Muthusamy, et al.
Publicado: (2012)

Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein Particles
por: Nakayama, Tomoko, et al.
Publicado: (2012)

Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
por: Brown, Christopher R, et al.
Publicado: (2020)

Efficient Downregulation of Alk4 in Skeletal Muscle After Systemic Treatment with Conjugated siRNAs in a Mouse Model for Duchenne Muscular Dystrophy
por: Engelbeen, Sarah, et al.
Publicado: (2023)

Structural basis for the synergy of 4′- and 2′-modifications on siRNA nuclease resistance, thermal stability and RNAi activity
por: Harp, Joel M, et al.
Publicado: (2018)

Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells
por: Khare, Purva, et al.
Publicado: (2021)

Overcoming GNA/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs
por: Schlegel, Mark K, et al.
Publicado: (2021)

Therapeutic siRNA silencing in inflammatory monocytes
por: Leuschner, Florian, et al.
Publicado: (2011)

Aminooxy Click Chemistry as a Tool for Bis-homo and Bis-hetero Ligand Conjugation to Nucleic Acids
por: Datta, Dhrubajyoti, et al.
Publicado: (2022)

Improved nucleic acid descriptors for siRNA efficacy prediction
por: Sciabola, Simone, et al.
Publicado: (2013)

The Roles of Individual Mammalian Argonautes in RNA Interference In Vivo
por: Ruda, Vera M., et al.
Publicado: (2014)

Oxygen-dependent, alternative promoter controls translation of tco1(+) in fission yeast
por: Sehgal, Alfica, et al.
Publicado: (2008)

5′ Unlocked Nucleic Acid Modification Improves siRNA Targeting
por: Snead, Nicholas M, et al.
Publicado: (2013)

Application of Locked Nucleic Acid Oligonucleotides for siRNA Preclinical Bioanalytics
por: Thayer, Mai B., et al.
Publicado: (2019)

SREBP Controls Oxygen-Dependent Mobilization of Retrotransposons in Fission Yeast
por: Sehgal, Alfica, et al.
Publicado: (2007)

Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain
por: Rungta, Ravi L, et al.
Publicado: (2013)

Centyrin ligands for extrahepatic delivery of siRNA
por: Klein, Donna, et al.
Publicado: (2021)

siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2
por: Elkayam, Elad, et al.
Publicado: (2017)

siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2
por: Elkayam, Elad, et al.
Publicado: (2017)

Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality
por: Elmén, Joacim, et al.
Publicado: (2005)

Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters
por: Watts, Jonathan K., et al.
Publicado: (2010)

Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
por: Janas, Maja M, et al.
Publicado: (2019)

Knocking down barriers: advances in siRNA delivery
por: Whitehead, Kathryn A., et al.
Publicado: (2009)

Synthesis, chirality-dependent conformational and biological properties of siRNAs containing 5′-(R)- and 5′-(S)-C-methyl-guanosine
por: Mikami, Atsushi, et al.
Publicado: (2020)

Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc–siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5′-exonuclease
por: Kumar, Pawan, et al.
Publicado: (2020)

Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
por: Janas, Maja M., et al.
Publicado: (2018)

Spherical Nucleic Acid Architecture Can Improve the Efficacy of Polycation-Mediated siRNA Delivery
por: Melamed, Jilian R., et al.
Publicado: (2018)

Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs
por: Khanali, Javad, et al.
Publicado: (2021)

Tissue-specific gene silencing monitored in circulating RNA
por: Sehgal, Alfica, et al.
Publicado: (2014)

Nanoparticle-encapsulated siRNAs for gene silencing in the haematopoietic stem-cell niche
por: Krohn-Grimberghe, Marvin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4ll4829gj28trvc211691v2job